Celldex Historical Cash Flow
| CLDX Stock | USD 26.04 0.63 2.48% |
Analysis of Celldex Therapeutics cash flow over time is an excellent tool to project Celldex Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 14.1 M or Depreciation of 2.5 M as it is a great indicator of Celldex Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Celldex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Celldex Therapeutics is a good buy for the upcoming year.
Celldex |
About Celldex Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Celldex balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Celldex's non-liquid assets can be easily converted into cash.
Celldex Therapeutics Cash Flow Chart
Add Fundamental
Depreciation
Depreciation indicates how much of Celldex Therapeutics value has been used up. For tax purposes Celldex Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Celldex Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Celldex Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Change To Netincome is fairly stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Begin Period Cash Flow | 43.8M | 39.1M | 29.4M | 31.2M | End Period Cash Flow | 39.1M | 29.4M | 34.8M | 32.4M |
Celldex Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Celldex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Celldex Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (13.1M) | 32.6M | (4.7M) | (9.7M) | 5.4M | 5.7M | |
| Free Cash Flow | (47.1M) | (42.0M) | (62.2M) | (105.6M) | (109.1M) | (103.7M) | |
| Change In Working Capital | (4.3M) | (299K) | (1.1M) | (3.9M) | 13.5M | 14.1M | |
| Depreciation | 4.9M | 3.9M | 3.1M | 2.9M | 3.0M | 2.5M | |
| Other Non Cash Items | (1.3M) | 13.0M | (1.1M) | (5.8M) | (6.2M) | (5.9M) | |
| Capital Expenditures | 731K | 1.6M | 1.2M | 1.8M | 1.8M | 1.4M | |
| Total Cash From Operating Activities | (46.4M) | (40.4M) | (60.9M) | (103.7M) | (107.3M) | (101.9M) | |
| Net Income | (50.9M) | (59.8M) | (70.5M) | (112.3M) | (141.4M) | (134.4M) | |
| End Period Cash Flow | 11.2M | 43.8M | 39.1M | 29.4M | 34.8M | 32.4M | |
| Begin Period Cash Flow | 24.3M | 11.2M | 43.8M | 39.1M | 29.4M | 31.2M | |
| Other Cashflows From Financing Activities | 9K | 434K | 2.5M | 4.1M | 2.2M | 2.1M | |
| Total Cash From Financing Activities | 16.3M | 171.2M | 272.4M | 4.1M | 218.5M | 229.4M | |
| Sale Purchase Of Stock | 29.4M | 16.3M | 171.2M | 272.4M | 313.2M | 328.9M | |
| Stock Based Compensation | 4.6M | 3.9M | 9.0M | 15.6M | 23.9M | 22.7M | |
| Total Cashflows From Investing Activities | 17.1M | (98.2M) | (216.2M) | 89.9M | 80.9M | 85.0M | |
| Other Cashflows From Investing Activities | 20K | 55K | 27K | 69K | 79.4K | 75.4K | |
| Change To Liabilities | (6.9M) | 1.6M | 3.7M | 3.1M | 2.8M | 3.0M | |
| Investments | 17.8M | (98.2M) | (214.9M) | 89.9M | (105.8M) | (100.5M) | |
| Change Receivables | (777K) | 2.3M | (787K) | 1.6M | 1.8M | 1.9M | |
| Cash And Cash Equivalents Changes | (16.0M) | (13.1M) | 32.6M | (4.7M) | (4.2M) | (4.0M) | |
| Cash Flows Other Operating | (149.4M) | (50.6M) | (60.1M) | (72.4M) | (65.1M) | (68.4M) | |
| Change To Netincome | 5.1M | 15.7M | 7.6M | 9.6M | 11.0M | 15.7M | |
| Change To Operating Activities | (6.3M) | (1.2M) | (6.3M) | (6.8M) | (6.2M) | (5.9M) | |
| Issuance Of Capital Stock | 16.2M | 170.8M | 269.9M | 0.0 | 216.2M | 128.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.